Compare · CRL vs ISPC
CRL vs ISPC
Side-by-side comparison of Charles River Laboratories International Inc. (CRL) and iSpecimen Inc. (ISPC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CRL and ISPC operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- CRL is the larger of the two at $8.73B, about 2012.5x ISPC ($4.3M).
- Over the past year, CRL is up 26.5% and ISPC is down 94.0% - CRL leads by 120.5 points.
- CRL has been more active in the news (20 items in the past 4 weeks vs 4 for ISPC).
- CRL has more recent analyst coverage (25 ratings vs 2 for ISPC).
- Company
- Charles River Laboratories International Inc.
- iSpecimen Inc.
- Price
- $186.54+2.88%
- $2.97-1.33%
- Market cap
- $8.73B
- $4.3M
- 1M return
- +2.54%
- -43.21%
- 1Y return
- +26.51%
- -94.01%
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NYSE
- NASDAQ
- IPO
- 2000
- 2021
- News (4w)
- 20
- 4
- Recent ratings
- 25
- 2
Charles River Laboratories International Inc.
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains and purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets and chemical compounds through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company was founded in 1947 and is based in Wilmington, Massachusetts.
Latest CRL
- Director Foster James C gifted 183,361 shares and received a gift of 183,361 shares, decreasing direct ownership by 62% to 106,596 units (SEC Form 4)
- Chief Executive Officer Girshick Birgit gifted 3,386 shares and received a gift of 3,386 shares, decreasing direct ownership by 9% to 36,013 units (SEC Form 4)
- CEVP, Disc & Safety Assessment Parisotto Shannon M gifted 1,529 shares and received a gift of 1,529 shares, decreasing direct ownership by 13% to 9,853 units (SEC Form 4)
- Director Barg Steven was granted 422 shares, increasing direct ownership by 15% to 3,287 units (SEC Form 4)
- EVP & Chief Financial Officer Coleman Glenn was granted 6,640 shares, increasing direct ownership by 31% to 27,752 units (SEC Form 4)
- EVP, Chief Information Officer Mintz Mark was granted 2,534 shares and covered exercise/tax liability with 369 shares, increasing direct ownership by 29% to 9,546 units (SEC Form 4)
- EVP, Corp Strategy & Develop Laplume Joseph W was granted 5,257 shares and covered exercise/tax liability with 979 shares, increasing direct ownership by 16% to 31,298 units (SEC Form 4)
- SVP, Finance and CAO Knell Michael Gunnar was granted 1,837 shares and covered exercise/tax liability with 200 shares, increasing direct ownership by 11% to 16,152 units (SEC Form 4)
- Chief Executive Officer Girshick Birgit was granted 9,961 shares and covered exercise/tax liability with 1,582 shares, increasing direct ownership by 27% to 39,399 units (SEC Form 4)
- Director Foster James C covered exercise/tax liability with 1,596 shares, decreasing direct ownership by 0.57% to 279,957 units (SEC Form 4)
Latest ISPC
- SEC Form S-3 filed by iSpecimen Inc.
- iSpecimen Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- iSpecimen Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form DEFA14A filed by iSpecimen Inc.
- SEC Form D filed by iSpecimen Inc.
- iSpecimen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- E.F. Hutton & Co. Serves as Exclusive Placement Agent on iSpecimen Inc. $2.5 Million Private Placement
- iSpecimen Inc. Announces Pricing of Approximately $2.5 Million Private Placement
- iSpecimen Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- iSpecimen Inc. filed SEC Form 8-K: Other Events